Chemical Properties:
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer with High Purity and Stable Quality Chemical Name: Zoledronic Acid Monohydrate CAS: 165800-06-6 A highly potent bisphosphonate and activator of PKC API High Quality, Commercial Production| Item | Specifications |
| Appearance | White or Almost Crystalline Powder |
| Identification | IR Spectrum; HPLC ChromatogramUV-Vis: There is a maximum absorbance at 210nm |
| pH | 2.0~4.0 |
| Solubility | Sparingly soluble in 0.1N sodium hydroxide solution, slightly soluble in water and 0.1N hydrochloric acid, practically insoluble in ethanol. |
| Clarity and Color | The solution should be clear and colorless; if opalescent, should not more opalescent than reference suspension 1; if colored, not more intensely colored than Y2 |
| Single Impurity | ≤0.50% |
| Total Impurities | ≤1.0% |
| Loss on Drying | 5.0%~8.0% |
| Chloride | ≤0.02% |
| Phosphate | ≤0.50% |
| Phosphite | ≤0.50% |
| Heavy Metals | ≤10ppm |
| Purity | ≥99.0% |
| Test Standard | Enterprise Standard |
| Usage | API |
Description:
Specifications:
Package & Storage:
| Chemical Name | Zoledronic Acid Monohydrate |
| CAS Number | 165800-06-6 |
| CAT Number | RF-API56 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C5H12N2O8P2 |
| Molecular Weight | 290.1 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Zoledronic acid monohydrate is a highly potent bisphosphonate and activator of PKC.Zoledronic acid monohydrate is a heterocyclic bisphosphonate that is considered to have the highest potency of bisphosphonates for suppression of increased bone resorption and has been used in several osteoporosis studies. Zoledronic acid monohydrate is an inhibitor of ASM and FDPS and an activator of PKC. Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget's disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones.
